Nexterone (Amiodarone Hci)

Concomitant use can potentiate electrophysiologic and hemodynamic effects, resulting in bradycardia, sinus arrest, and AV block.

Amiodarone increases serum digoxin concentration, requiring dose reduction by half or discontinuation and monitoring for toxicity.

Concomitant use can potentiate electrophysiologic and hemodynamic effects, resulting in bradycardia, sinus arrest, and AV block.

Metabolism of flecainide is inhibited by amiodarone. Initiate at lower dose and reduce dose by 30-50% when adding amiodarone.

Exposure to amiodarone is significantly increased. Patients should avoid grapefruit juice beverages.

Concomitant use can potentiate electrophysiologic and hemodynamic effects, resulting in bradycardia, sinus arrest, and AV block.

7.3 Serious Symptomatic Bradycardia When Co-administered with Ledipasvir/Sofosbuvir or with Sofosbuvir with Simeprevir Postmarketing cases of symptomatic bradycardia, some requiring pacemaker insertion and at least one fatal, have been reported when ledipasvir/sofosbuvir or sofosbuvir with simeprevir were initiated in patients on amiodarone.

Co-administration increases risk of Torsade de Pointes due to QT prolongation.

Concomitant use can potentiate electrophysiologic and hemodynamic effects, resulting in bradycardia, sinus arrest, and AV block.

Metabolism of procainamide is inhibited by amiodarone. Initiate at lower dose and reduce dose by 30-50% when adding amiodarone.

Metabolism of quinidine is inhibited by amiodarone. Initiate at lower dose and reduce dose by 30-50% when adding amiodarone.

7.3 Serious Symptomatic Bradycardia When Co-administered with Ledipasvir/Sofosbuvir or with Sofosbuvir with Simeprevir Postmarketing cases of symptomatic bradycardia, some requiring pacemaker insertion and at least one fatal, have been reported when ledipasvir/sofosbuvir or sofosbuvir with simeprevir were initiated in patients on amiodarone.

7.3 Serious Symptomatic Bradycardia When Co-administered with Ledipasvir/Sofosbuvir or with Sofosbuvir with Simeprevir Postmarketing cases of symptomatic bradycardia, some requiring pacemaker insertion and at least one fatal, have been reported when ledipasvir/sofosbuvir or sofosbuvir with simeprevir were initiated in patients on amiodarone.

Concomitant use can potentiate electrophysiologic and hemodynamic effects, resulting in bradycardia, sinus arrest, and AV block.

May inhibit CYP450 enzymes, increasing amiodarone exposure and potential for interactions.

May induce CYP450 enzymes, potentially decreasing amiodarone exposure.

Lower starting and maintenance doses of other CYP3A4 substrates (e.g., atorvastatin) may be required as amiodarone may increase the plasma concentration of these drugs.

Limit the daily dose of lovastatin to 40 mg.

HMG-CoA Reductase Inhibitors: Limit the dose of simvastatin in patients on amiodarone to 20 mg daily.